Share-based Payment Arrangement, Expense of Seres Therapeutics, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Seres Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Seres Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,482,000, a 52% decline year-over-year.
  • Seres Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $11,406,000, a 49% decline year-over-year.
  • Seres Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,971,000, a 39% decline from 2023.
  • Seres Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $34,101,000, a 34% increase from 2022.
  • Seres Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $25,482,000, a 26% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Seres Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $11,406,000 $2,482,000 -$2,701,000 -52% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $14,107,000 $2,340,000 -$3,194,000 -58% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $17,301,000 $2,819,000 -$3,670,000 -57% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $20,971,000 $3,765,000 -$1,321,000 -26% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $22,292,000 $5,183,000 -$3,490,000 -40% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $25,782,000 $5,534,000 -$7,958,000 -59% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $33,740,000 $6,489,000 -$361,000 -5.3% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $34,101,000 $5,086,000 -$2,205,000 -30% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $36,306,000 $8,673,000 +$2,309,000 +36% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $33,997,000 $13,492,000 +$6,744,000 +100% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $27,253,000 $6,850,000 +$1,771,000 +35% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $25,482,000 $7,291,000 +$1,617,000 +28% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
Q3 2022 $23,865,000 $6,364,000 +$518,000 +8.9% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $23,347,000 $6,748,000 +$1,670,000 +33% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $21,677,000 $5,079,000 +$1,455,000 +40% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $20,222,000 $5,674,000 +$2,972,000 +110% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
Q3 2021 $17,250,000 $5,846,000 +$3,597,000 +160% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $13,653,000 $5,078,000 +$3,164,000 +165% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $10,489,000 $3,624,000 +$1,665,000 +85% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $8,824,000 $2,702,000 +$557,000 +26% 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
Q3 2020 $8,267,000 $2,249,000 +$212,000 +10% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $8,055,000 $1,914,000 -$183,000 -8.7% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $8,238,000 $1,959,000 -$106,000 -5.1% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $8,344,000 $2,145,000 -$1,609,000 -43% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $9,953,000 $2,037,000 -$2,280,000 -53% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $12,233,000 $2,097,000 -$2,237,000 -52% 01 Apr 2019 30 Jun 2019 10-Q 28 Jul 2020 2020 Q2
Q1 2019 $14,470,000 $2,065,000 -$2,171,000 -51% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $16,641,000 $3,754,000 -$457,000 -11% 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
Q3 2018 $17,098,000 $4,317,000 -$52,000 -1.2% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $17,150,000 $4,334,000 -$169,000 -3.8% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $17,319,000 $4,236,000 -$43,000 -1% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $17,362,000 $4,211,000 +$219,000 +5.5% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $17,143,000 $4,369,000 +$125,000 +2.9% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $17,018,000 $4,503,000 -$214,000 -4.5% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $17,232,000 $4,279,000 +$375,000 +9.6% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $16,857,000 $3,992,000 +$1,205,000 +43% 01 Oct 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
Q3 2016 $15,652,000 $4,244,000 +$1,737,000 +69% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $13,915,000 $4,717,000 +$1,644,000 +53% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $12,271,000 $3,904,000 +$2,577,000 +194% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $9,694,000 $2,787,000 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
Q3 2015 $2,507,000 +$1,904,000 +316% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $3,073,000 +$3,021,000 +5810% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $1,327,000 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1
Q3 2014 $603,000 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $52,000 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2

Seres Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,971,000 -$13,130,000 -39% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $34,101,000 +$8,619,000 +34% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $25,482,000 +$5,260,000 +26% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
2021 $20,222,000 +$11,398,000 +129% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 $8,824,000 +$480,000 +5.8% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2023 2022 FY
2019 $8,344,000 -$8,297,000 -50% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $16,641,000 -$721,000 -4.2% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
2017 $17,362,000 +$505,000 +3% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $16,857,000 +$7,163,000 +74% 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
2015 $9,694,000 +$7,626,000 +369% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $2,068,000 +$1,859,000 +889% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $209,000 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.